Clinical trial finds dendritic cell vaccine safe, induced immune responses in patients with multiple myeloma

by

A dendritic cell vaccine administered before and after autologous stem cell transplant (ASCT) was safe and immunogenic and was associated with durable clinical responses in patients with high-risk multiple myeloma, according to research published in Clinical Cancer Research.

Leave A Comment

Your email address will not be published. Required fields are marked *